Skip to content

Implementing Artificial Intelligence to Prevent Vision Loss From Diabetes

Implementing Artificial Intelligence (AI) to Prevent Vision Loss From Diabetes

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07559292
Enrollment
1700
Registered
2026-04-30
Start date
2026-02-15
Completion date
2027-02-01
Last updated
2026-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Vision Disorders

Keywords

Artificial Intelligence, AI, diabetic eye disease, pragmatic

Brief summary

This pragmatic clinical trial is being conducted to test the effectiveness of AI in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 4 primary care clinics. This is an autonomous AI-based screening to detect diabetic eye disease at primary care visits.

Detailed description

Four clinics from two health systems will be recruited, with two clinics from each health system and randomly assigned to either usual-care or the AI Intervention with 2 clinics assigned to each arms. Beginning in month 3, a 6-week baseline period will be conducted in all clinics, followed by a 4-month intervention period for the two clinics assigned to AI. Primary Objective: Compare the odds of patients, who get eye screening in the AI and usual-care arms within 5 months of the recommendation Secondary Objective: 1. Compare the odds of patients, who completed follow-up with recommended eye care in the AI and usual-care arms within 5 months of the recommendation 2. Compare the odds of patients in different demographic groups who receive eye screening in the AI and usual-care arms within 5 months of the recommendation

Interventions

OTHERAI

AI-based eye screening program

OTHERUsual Practice

PCP recommends annual vision screening, a separate visit entirely

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Parallel cluster randomized control trial

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Clinic Inclusion Criteria: * Serve at least 267 patients with diabetes during the study period * No point-of-care screening system in use for diabetic eye disease * Agree to share limited identifiers data as requested Patient Inclusion Criteria: * Age 22 years or older * Diagnosis of type 1 or 2 diabetes * No known diabetic eye disease * No diabetic eye exam in the past 12 months

Exclusion criteria

* Have a documented eye exam in the electronic health record within 12 months of the date of the primary care visit. * Contraindication includes diagnosed with macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion. * Pregnant

Design outcomes

Primary

MeasureTime frame
Proportion of patients who get eye screening in the AI and usual-care arms within 5 months of the recommendationup to 5 months

Secondary

MeasureTime frame
Proportion of patients, who completed follow-up with recommended eye care in the AI and usual-care arms within 5 months of the recommendationup to 5 months
Proportion of patients in different demographic groups who receive eye screening in the AI and usual-care arms within 5 months of the recommendationup to 5 months

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRoomsa Channa, MD

University of Wisconsin, Madison

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 1, 2026